Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Trastuzumab Rezetecan ± Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma
ChiCTR2500110227Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab rezetecan and adebrelimab in transitional cell carcinoma (TCC) (3 cohorts), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective Response Rate. Started Oct 2025; status: recruiting.
02
Drugs
trastuzumab rezetecanadebrelimab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2500110227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110227.